New CEO to Drive Clinical Phase Development

Zelluna Immunotherapy, a biotechnology company specialising in T-cell receptor (TCR) immunotherapies targeting a broad range of solid cancers, has appointed Miguel Forte as chief executive officer (CEO).

“Zelluna is developing a unique immunotherapy portfolio of non-engineered tumour specific T-cell receptors (TCRs) isolated from long term survivors from cancer vaccine trials conducted by former Professor Gustav Gaudernack’s group at the Oslo University Hospital. This enables Zelluna to target some of the most common cancer antigens and cancer types. Its established partnerships also grant critical support including all capabilities of TCR development, one of Europe’s largest academic GMP cell therapy production facilities headed by Professor Gunnar Kvalheim and access to patients and clinical trial support through a dedicated Clinical Trial Unit,” said Anders Tuv, chairman of the board, Zelluna. “Appointing a CEO with the international experience and profile of Miguel Forte will be critical to further enhance the therapeutic, development and commercial potential of Zelluna and push its leadership position in the international TCR and immunotherapy marketplaces.”

Miguel is tasked with driving clinical translation of the TCR pipeline, developing new international scientific and commercial partnerships and forging relationships with the international investor communities.

With extensive commercial experience in the regenerative medicine, cell therapy, medical and regulatory affairs industries, Miguel is also currently chief commercialisation officer and chair of the commercialisation committee for the International Society of Cellular Therapy, the global society of clinicians, researchers, regulatory specialists, technologists and industry partners in the cell therapy sector.